|
|
感染新型冠状病毒的糖尿病患者的预后新预测模型开发及其预测价值评估
|
Abstract:
目的：探讨基于风险因素构建的预测模型，预测糖尿病患者感染SARS-CoV-2 (新型冠状病毒)的预后。方法：回顾性分析了239例2022年12月至2023年1月重庆医科大学附属第二医院收治的确诊为SARS-CoV-2感染的糖尿病住院患者。通过电子病历系统收集患者的相关资料。其中死亡43例，好转出院196例。将患者分为死亡组及存活组，采用单因素Logistic回归分析筛选相关候选因子，再通过多因素Logistic回归分析构建预测模型，使用Bootstrap方法进行内部验证，利用校准曲线、DCA曲线对模型性能进行评估。结果：通过Logistic回归分析，最终有5个因素纳入预测模型，分别为C反应蛋白(CRP) [OR 1.01 (95% CI 1.02)]、白介素6 [OR 1.01 (95% CI 1.01)]、白介素10 [OR 1.04 (95% CI 1.08)]、血氯[OR 0.87 (95% CI 0.99)]、血钠[OR 1.31 (95% CI 1.55)]。经验证该模型在内部验证队列中表现良好。结论：我们通过Logistic回归分析构建的糖尿病患者感染SARS-CoV-2的预后预测模型能够可视化预测结果，并且具有较好的预测效能，对临床制定干预决策有指导意义。
Objective: To explore a predictive model based on risk factors to predict the prognosis of diabetic patients infected with SARS-CoV-2. Methods: 239 diabetic inpatients with SARS-CoV-2 infection admitted to the Second Affiliated Hospital of Chongqing Medical University from December 2022 to January 2023 were analyzed retrospectively. The relevant data of the patients was collected by the electronic medical record system. The patients were divided into a death group and a survival group, and the relevant candidate factors were screened using univariate logistic regression analysis, and then the prediction model was constructed by multi-factor logistic regression analysis. The model was internally verified by the Bootstrap method, and the performance of the model was evaluated by the calibration curve and DCA curve. Results: Through logistic regression analysis, five factors were included in the prediction model: C-reactive protein (CRP) [OR 1.01 (95% CI 1.02)], IL-6 [OR 1.01 (95% CI 1.01)], IL-10 [OR 1.04 (95% CI 1.08)], and blood chlorine [OR 0.87 (95% CI 0.99)] and serum sodium [OR 1.31 (95% CI 1.55)]. It is proved that the model performs well in the internal verification queue. Conclusion: The prognosis prediction model of diabetic patients infected with SARS-CoV-2 constructed by Logistic regression analysis can visually predict the results, and has a good predictive efficiency, which is of guiding significance for clinical intervention decision-making.
| [1] | 张佳琦, 刘国华, 黄建安. 新冠病毒奥密克戎变异株的特点与防控措施[J]. 中国感染控制杂志, 2022, 8(21): 816-822. |
| [2] | Li, B., Yang, J., Zhao, F., et al. (2023) Prevalence and Impact of Cardiovascular Metabolic Diseases on COVID-19 in China. Nature Public Health Emergency Collection. |
| [3] | Buscemi, S., Corleo, D. and Randazzo, C. (2021) Risk Factors for COVID-19: Diabetes, Hypertension, and Obesity. In: Asea, A.A.A. and Kaur, P., Eds., Coronavirus Therapeutics—Volume II, Springer International Publishing, 115-129. https://doi.org/10.1007/978-3-030-85113-2_7 |
| [4] | Liang, C., Zhang, W., Li, S. and Qin, G. (2021) Coronary Heart Disease and COVID-19: A Meta-Analysis. Medicina Clínica, 156, 547-554. https://doi.org/10.1016/j.medcli.2020.12.017 |
| [5] | Petrilli, C.M., Jones, S.A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., et al. (2020) Factors Associated with Hospital Admission and Critical Illness among 5279 People with Coronavirus Disease 2019 in New York City: Prospective Cohort Study. BMJ, 369, m1966. https://doi.org/10.1136/bmj.m1966 |
| [6] | Bode, B., Garrett, V., Messler, J., McFarland, R., Crowe, J., Booth, R., et al. (2020) Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. Journal of Diabetes Science and Technology, 14, 813-821. https://doi.org/10.1177/1932296820924469 |
| [7] | Holman, N., Knighton, P., Kar, P., O’Keefe, J., Curley, M., Weaver, A., et al. (2020) Risk Factors for Covid-19-Related Mortality in People with Type 1 and Type 2 Diabetes in England: A Population-Based Cohort Study. The Lancet Diabetes & Endocrinology, 8, 823-833. https://doi.org/10.1016/s2213-8587(20)30271-0 |
| [8] | Holman, N. (2020) Associations of Type 1 and Type 2 Diabetes with COVID-19-Related Mortality in England: A Whole-Population Study. The Lancet Diabetes & Endocrinology, 8, 813-822. |
| [9] | 彭俊男, 迪戚, 宋玉燕, 等. 重庆市新型冠状病毒肺炎患者并发急性呼吸窘迫综合征风险预测模型的建立[J]. 重庆医科大学学报, 2020, 45(7): 853-857. |
| [10] | 中国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版) [J]. 国际流行病学传染病学杂志, 2022, 49(2): 73-80. |
| [11] | Tessema, S.K. and Nkengasong, J.N. (2021) Understanding COVID-19 in Africa. Nature Reviews Immunology, 21, 469-470. https://doi.org/10.1038/s41577-021-00579-y |
| [12] | Organization WH (2022) Enhancing Response to Omicron SARS-CoV-2 Variant: Technical Brief and Priority Actions for Member States. Health and Safety, 13-14. |
| [13] | Soraya, G.V. and Ulhaq, Z.S. (2020) Crucial Laboratory Parameters in COVID-19 Diagnosis and Prognosis: An Updated Meta-Analysis. Medicina Clínica, 155, 143-151. https://doi.org/10.1016/j.medcli.2020.05.017 |
| [14] | Rahman, M.A., Shanjana, Y., Tushar, M.I., Mahmud, T., Rahman, G.M.S., Milan, Z.H., et al. (2021) Hematological Abnormalities and Comorbidities Are Associated with COVID-19 Severity among Hospitalized Patients: Experience from Bangladesh. PLOS ONE, 16, e0255379. https://doi.org/10.1371/journal.pone.0255379 |
| [15] | 吴俣, 刘珏, 刘民, 等. 新型冠状病毒Omicron变异株的流行病学特征及防控研究[J]. 中国全科医学, 2022, 25(1): 14-19. |
| [16] | Ye, Q., Wang, B. and Mao, J. (2020) The Pathogenesis and Treatment of the “Cytokine Storm” in COVID-19. Journal of Infection, 80, 607-613. https://doi.org/10.1016/j.jinf.2020.03.037 |
| [17] | Coomes, E.A. and Haghbayan, H. (2020) Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis. Reviews in Medical Virology, 30, 1-9. https://doi.org/10.1002/rmv.2141 |
| [18] | Ramasamy, S. and Subbian, S. (2021) Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis. Clinical Microbiology Reviews, 34, 607-613. https://doi.org/10.1128/cmr.00299-20 |
| [19] | Li, X. and Ma, X. (2020) Acute Respiratory Failure in COVID-19: Is It “Typical” ARDS? Critical Care, 24, Article No. 198. https://doi.org/10.1186/s13054-020-02911-9 |
| [20] | Pourfridoni, M., Abbasnia, S.M., Shafaei, F., Razaviyan, J. and Heidari-Soureshjani, R. (2021) Fluid and Electrolyte Disturbances in COVID-19 and Their Complications. BioMed Research International, 2021, Article ID: 6667047. https://doi.org/10.1155/2021/6667047 |
| [21] | Taci Hoca, N. and Berktaş, B.M. (2022) Baseline Electrolyte Disorders Predict Disease Severity and Mortality in Patients with COVID-19. Medicine, 101, e32397. https://doi.org/10.1097/md.0000000000032397 |
| [22] | Hur, K., Price, C.P.E., Gray, E.L., Gulati, R.K., Maksimoski, M., Racette, S.D., et al. (2020) Factors Associated with Intubation and Prolonged Intubation in Hospitalized Patients with COVID-19. Otolaryngology—Head and Neck Surgery, 163, 170-178. https://doi.org/10.1177/0194599820929640 |
| [23] | Lu, G., Zhang, Y., Zhang, H., Ai, J., He, L., Yuan, X., et al. (2022) Geriatric Risk and Protective Factors for Serious COVID-19 Outcomes among Older Adults in Shanghai Omicron Wave. Emerging Microbes & Infections, 11, 2045-2054. https://doi.org/10.1080/22221751.2022.2109517 |
| [24] | Kim, L., Garg, S., O’Halloran, A., Whitaker, M., Pham, H., Anderson, E.J., et al. (2020) Risk Factors for Intensive Care Unit Admission and In-Hospital Mortality among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-Net). Clinical Infectious Diseases, 72, e206-e214. https://doi.org/10.1093/cid/ciaa1012 |
| [25] | Dietz, W. and Santos-Burgoa, C. (2020) Obesity and Its Implications for COVID-19 Mortality. Obesity, 28, 1005-1005. https://doi.org/10.1002/oby.22818 |
| [26] | 陆钦菊, 王进京, 傅小云. COVID-19相关ARDS: 从病理, 病理生理到临床管理[J]. 遵义医科大学学报, 2021(4): 545-549. |
| [27] | Anker, M.S., Landmesser, U., von Haehling, S., Butler, J., Coats, A.J.S. and Anker, S.D. (2020) Weight Loss, Malnutrition, and Cachexia in COVID-19: Facts and Numbers. Journal of Cachexia, Sarcopenia and Muscle, 12, 9-13. https://doi.org/10.1002/jcsm.12674 |
| [28] | Burgos, R., García-Almeida, J.M., Matía-Martín, P., Palma, S., Sanz-Paris, A., Zugasti, A., et al. (2022) Malnutrition Management of Hospitalized Patients with Diabetes/Hyperglycemia and COVID-19 Infection. Reviews in Endocrine and Metabolic Disorders, 23, 205-213. https://doi.org/10.1007/s11154-022-09714-z |
| [29] | Yu, C., Wong, R.S., Wu, E.B., Kong, S., Wong, J., Yip, G.W., et al. (2006) Cardiovascular Complications of Severe Acute Respiratory Syndrome. Postgraduate Medical Journal, 82, 140-144. https://doi.org/10.1136/pgmj.2005.037515 |
| [30] | Tajbakhsh, A., Gheibi Hayat, S.M., Taghizadeh, H., Akbari, A., inabadi, M., Savardashtaki, A., et al. (2020) COVID-19 and Cardiac Injury: Clinical Manifestations, Biomarkers, Mechanisms, Diagnosis, Treatment, and Follow-Up. Expert Review of Anti-Infective Therapy, 19, 345-357. https://doi.org/10.1080/14787210.2020.1822737 |
| [31] | Huh, K., Kim, Y., Ji, W., Kim, D.W., Lee, E., Kim, J., et al. (2021) Decrease in Hospital Admissions for Respiratory Diseases during the COVID-19 Pandemic: A Nationwide Claims Study. Thorax, 76, 939-941. https://doi.org/10.1136/thoraxjnl-2020-216526 |
| [32] | Alsallakh, M.A., Sivakumaran, S., Kennedy, S., Vasileiou, E., Lyons, R.A., Robertson, C., et al. (2021) Impact of COVID-19 Lockdown on the Incidence and Mortality of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: National Interrupted Time Series Analyses for Scotland and Wales. BMC Medicine, 19, Article No. 124. https://doi.org/10.1186/s12916-021-02000-w |
| [33] | Aveyard, P., Gao, M., Lindson, N., Hartmann-Boyce, J., Watkinson, P., Young, D., et al. (2021) Association between Pre-Existing Respiratory Disease and Its Treatment, and Severe COVID-19: A Population Cohort Study. The Lancet Respiratory Medicine, 9, 909-923. https://doi.org/10.1016/s2213-2600(21)00095-3 |
| [34] | Heinen, N., Meister, T.L., Klöhn, M., Steinmann, E., Todt, D. and Pfaender, S. (2021) Antiviral Effect of Budesonide against SARS-CoV-2. Viruses, 13, Article No. 1411. https://doi.org/10.3390/v13071411 |
| [35] | Ramakrishnan, S., Nicolau, D.V., Langford, B., Mahdi, M., Jeffers, H., Mwasuku, C., et al. (2021) Inhaled Budesonide in the Treatment of Early COVID-19 (STOIC): A Phase 2, Open-Label, Randomised Controlled Trial. The Lancet Respiratory Medicine, 9, 763-772. https://doi.org/10.1016/s2213-2600(21)00160-0 |
| [36] | Yu, L.M., Bafadhel, M. and Dorward, J. (2021) Inhaled Budesonide for COVID-19 in People at High Risk of Complications in the Community in the UK (PRINCIPLE): A Randomised, Controlled, Open-Label, Adaptive Platform Trial (vol. 398, pg 843, 2021). The Lancet, 398, E12. |
| [37] | Gozdas, H.T., Kayis, S.A., Damarsoy, T., Ozsari, E., Turkoglu, M., Yildiz, I., et al. (2022) Multi-Inflammatory Index as a Novel Mortality Predictor in Critically Ill COVID-19 Patients. Journal of Intensive Care Medicine, 37, 1480-1485. https://doi.org/10.1177/08850666221100411 |
| [38] | Alharthy, A., Aletreby, W., Faqihi, F., Balhamar, A., Alaklobi, F., Alanezi, K., et al. (2020) Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study. Journal of Epidemiology and Global Health, 11, 98-104. https://doi.org/10.2991/jegh.k.200928.001 |
